PURPOSE: Advanced head and neck cancer shows hypoxia that results in biological changes to make the tumor cells more aggressive and less responsive to treatment resulting in poor survival. [F-18] fluoromisonidazole (FMISO) positron emission tomography (PET) has the ability to noninvasively quantify regional hypoxia. We investigated the prognostic effect of pretherapy FMISO-PET on survival in head and neck cancer. EXPERIMENTAL DESIGN: Seventy-three patients with head and neck cancer had pretherapy FMISO-PET and 53 also had fluorodeoxyglucose (FDG) PET under a research protocol from April 1994 to April 2004. RESULTS: Significant hypoxia was identified in 58 patients (79%). The mean FMISO tumor/bloodmax (T/Bmax) was 1.6 and the mean hypoxic volume (HV) was 40.2 mL. There were 28 deaths in the follow-up period. Mean FDG standard uptake value (SUV)max was 10.8. The median time for follow-up was 72 weeks. In a univariate analysis, T/Bmax (P=0.002), HV (P=0.04), and the presence of nodes (P=0.01) were strong independent predictors. In a multivariate analysis, including FDG SUVmax, no variable was predictive at P<0.05. When FDG SUVmax was removed from the model (resulting in n=73 with 28 events), nodal status and T/Bmax (or HV) were both highly predictive (P=0.02, 0.006 for node and T/Bmax, respectively; P=0.02 and 0.001 for node and HV, respectively). CONCLUSIONS: Pretherapy FMISO uptake shows a strong trend to be an independent prognostic measure in head and neck cancer.
PURPOSE: Advanced head and neck cancer shows hypoxia that results in biological changes to make the tumor cells more aggressive and less responsive to treatment resulting in poor survival. [F-18] fluoromisonidazole (FMISO) positron emission tomography (PET) has the ability to noninvasively quantify regional hypoxia. We investigated the prognostic effect of pretherapy FMISO-PET on survival in head and neck cancer. EXPERIMENTAL DESIGN: Seventy-three patients with head and neck cancer had pretherapy FMISO-PET and 53 also had fluorodeoxyglucose (FDG) PET under a research protocol from April 1994 to April 2004. RESULTS: Significant hypoxia was identified in 58 patients (79%). The mean FMISO tumor/bloodmax (T/Bmax) was 1.6 and the mean hypoxic volume (HV) was 40.2 mL. There were 28 deaths in the follow-up period. Mean FDG standard uptake value (SUV)max was 10.8. The median time for follow-up was 72 weeks. In a univariate analysis, T/Bmax (P=0.002), HV (P=0.04), and the presence of nodes (P=0.01) were strong independent predictors. In a multivariate analysis, including FDG SUVmax, no variable was predictive at P<0.05. When FDG SUVmax was removed from the model (resulting in n=73 with 28 events), nodal status and T/Bmax (or HV) were both highly predictive (P=0.02, 0.006 for node and T/Bmax, respectively; P=0.02 and 0.001 for node and HV, respectively). CONCLUSIONS: Pretherapy FMISO uptake shows a strong trend to be an independent prognostic measure in head and neck cancer.
Authors: W J Koh; J S Rasey; M L Evans; J R Grierson; T K Lewellen; M M Graham; K A Krohn; T W Griffin Journal: Int J Radiat Oncol Biol Phys Date: 1992 Impact factor: 7.038
Authors: D Rischin; L Peters; R Hicks; P Hughes; R Fisher; R Hart; M Sexton; I D'Costa; R von Roemeling Journal: J Clin Oncol Date: 2001-01-15 Impact factor: 44.544
Authors: M F Adam; E C Gabalski; D A Bloch; J W Oehlert; J M Brown; A A Elsaid; H A Pinto; D J Terris Journal: Head Neck Date: 1999-03 Impact factor: 3.147
Authors: J S Rasey; W J Koh; M L Evans; L M Peterson; T K Lewellen; M M Graham; K A Krohn Journal: Int J Radiat Oncol Biol Phys Date: 1996-09-01 Impact factor: 7.038
Authors: M Höckel; C Knoop; K Schlenger; B Vorndran; E Baussmann; M Mitze; P G Knapstein; P Vaupel Journal: Radiother Oncol Date: 1993-01 Impact factor: 6.280
Authors: Craig J Galbán; Stefanie Galbán; Marcian E Van Dort; Gary D Luker; Mahaveer S Bhojani; Alnawaz Rehemtulla; Brian D Ross Journal: Prog Mol Biol Transl Sci Date: 2010 Impact factor: 3.622
Authors: Alexandra Lucs; Benjamin Saltman; Christine H Chung; Bettie M Steinberg; David L Schwartz Journal: Head Neck Date: 2012-01-27 Impact factor: 3.147
Authors: Olivia J Kelada; Sara Rockwell; Ming-Qiang Zheng; Yiyun Huang; Yanfeng Liu; Carmen J Booth; Roy H Decker; Uwe Oelfke; Richard E Carson; David J Carlson Journal: Mol Imaging Biol Date: 2017-12 Impact factor: 3.488
Authors: B Clavo; F Robaina; D Fiuza; A Ruiz; M Lloret; D Rey-Baltar; P Llontop; A Riveros; J Rivero; F Castañeda; S Quintero; N Santana-Rodríguez Journal: Clin Transl Oncol Date: 2016-08-15 Impact factor: 3.405
Authors: Alexander M Spence; Mark Muzi; Kristin R Swanson; Finbarr O'Sullivan; Jason K Rockhill; Joseph G Rajendran; Tom C H Adamsen; Jeanne M Link; Paul E Swanson; Kevin J Yagle; Robert C Rostomily; Daniel L Silbergeld; Kenneth A Krohn Journal: Clin Cancer Res Date: 2008-05-01 Impact factor: 12.531
Authors: Jacobus F A Jansen; Heiko Schöder; Nancy Y Lee; Ya Wang; David G Pfister; Matthew G Fury; Hilda E Stambuk; John L Humm; Jason A Koutcher; Amita Shukla-Dave Journal: Int J Radiat Oncol Biol Phys Date: 2009-11-10 Impact factor: 7.038